OnKure Therapeutics (OKUR) Retained Earnings (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Retained Earnings came in at -$229.4 million in Q1 2026, down 34.43% YoY from -$349.8 million in Q1 2025, and down 7.08% on a QoQ basis from -$214.2 million in Q4 2025.
OnKure Therapeutics (OKUR) Retained Earnings (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Retained Earnings data on file, last reported at -$229.4 million in Q1 2026.
- Quarterly Retained Earnings fell 34.43% year-over-year to -$229.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$229.4 million (down 34.43% YoY) and the FY2025 annual result came in at -$214.2 million, down 38.47% from the prior year.
- Retained Earnings declined to -$229.4 million in Q1 2026, from -$214.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $310.0 million in Q3 2024 to a low of -$229.4 million in Q1 2026.
- A 5-year average of -$17.9 million and a median of -$110.1 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings sank 732592.31% — and 2024, when it surged 997325.81%.
- Tracing OKUR's Retained Earnings over 5 years: stood at -$136.7 million in 2022, then gained by 25.34% to -$102.1 million in 2023, then sank by 51.61% to -$154.7 million in 2024, then sank by 38.47% to -$214.2 million in 2025, then fell by 7.08% to -$229.4 million in 2026.
- The last three Retained Earnings figures came in at -$229.4 million (Q1 2026), -$214.2 million (Q4 2025), and $267.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 416.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 416.86 Mn |
| Mar 31, 2026 | -229.40 Mn |
| Dec 31, 2025 | -214.24 Mn |
| Sep 30, 2025 | 267.17 Mn |
| Jun 30, 2025 | 264.20 Mn |
| Mar 31, 2025 | -170.65 Mn |
| Dec 31, 2024 | -154.72 Mn |
| Sep 30, 2024 | 309.97 Mn |
| Jun 30, 2024 | 309.14 Mn |
| Mar 31, 2024 | -226.90 Mn |
| Dec 31, 2023 | -102.05 Mn |
| Sep 30, 2023 | -190.50 Mn |
| Jun 30, 2023 | -31,000.00 |
| Mar 31, 2023 | -151.79 Mn |
| Dec 31, 2022 | -136.68 Mn |
| Sep 30, 2022 | -26,000.00 |
| Jun 30, 2022 | -110.10 Mn |
| Mar 31, 2022 | 233.02 Mn |
| Dec 31, 2021 | -84.73 Mn |
| Sep 30, 2021 | -74.10 Mn |